{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:43:56Z","timestamp":1758127436751},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":5585,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1992,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>OBJECTIVE The aim of the study was to assess whether the immunoreactive inhibin response to ovarian stimulation in polycystic ovarian syndrome was of predictive value for the outcome of ovulation induction.<\/jats:p><jats:p>DESIGN Daily injections of purified FSH (Metrodin, Serono Laboratories, UK) were administered for the purpose of inducing development and ovulation of a single follicle.<\/jats:p><jats:p>PATIENTS All patients had anovulatory infertility secondary to polycystic ovarian syndrome and were resistant to clomiphene citrate.<\/jats:p><jats:p>MEASUREMENTS Alternate day serum samples were obtained for measurement of gonadotropins, sex steroids and inhibin by radioimmunoassay. Alternate day ovarian ultrasound scans were carried out to monitor follicular development.<\/jats:p><jats:p>RESULTS There was a high incidence of multiple follicular development (MFD) (10.2 \u00b1 7.1 (standard deviation) follicles). There was a close relationship between the number of follicles on the day of the ovulatory trigger and serum oestradiol (E<jats:sub>2<\/jats:sub>) levels (<jats:italic>R<\/jats:italic>= 0\u2013 97, <jats:italic>P<\/jats:italic> &lt; 0.001). This relationship was not seen with serum immunoreactive inhibin levels (<jats:italic>R<\/jats:italic>= 0.31). The cycles were divided into two groups depending whether there was or was not MFD (more than five follicles &lt; 7 mm in diameter on day of hCG administration). The MFD group had 15.6 \u00b1 8.5 follicles and the non\u2010MFD group 3.2 \u00b1 1.6 follicles. There was no difference in the circulating E<jats:sub>2<\/jats:sub> concentration (pmol\/l) per follicle between the two groups (non\u2010MFD cycles, <jats:italic>n<\/jats:italic>= 6,345 \u00b1 28.9; MFD cycles, <jats:italic>n<\/jats:italic>= 8, 308 \u00b1 40.29). However, the immunoreactive inhibin concentration (U\/ml) per follicle was lower, <jats:italic>P<\/jats:italic> &lt; 0.001, in the MFD group (4.3 \u00b1 1 6 <jats:italic>vs<\/jats:italic> 6.9 \u00b1 0.5).<\/jats:p><jats:p>The maximum and mean follicle diameter were lower, <jats:italic>P<\/jats:italic> &lt; 0.01, in the MFD group (maximum follicle size 16.5 \u00b1 3.9 <jats:italic>vs<\/jats:italic> 21.2 \u00b1 1.5 mm, mean follicle size 11.5 \u00b1 2 <jats:italic>vs<\/jats:italic> 14.9 \u00b1 2.3). When individual cycles were examined E<jats:sub>2<\/jats:sub> and immunoreactive inhibin secretion rose in parallel in cycles with less than five follicles with a rapid rise occurring when the follicles reached about 12 <jats:italic>mm<\/jats:italic> in diameter. In cycles where there was MFD there was a disparity between E<jats:sub>2<\/jats:sub> and immunoreactive inhibin secretion with E<jats:sub>2<\/jats:sub> levels rising 4.3 \u00b1 1.4 days before immunoreactive inhibin levels.<\/jats:p><jats:p>CONCLUSION These data suggest that in cycles where there are multiple small follicles, E<jats:sub>2<\/jats:sub> secretion is maintained whereas immunoreactive inhibin secretion is substantially lower. Thus, in view of the disparity between E<jats:sub>2<\/jats:sub> and immunoreactive inhibin secretion evident in the MFD group, measurement of immunoreactive serum inhibin concentration may be a better indicator of granulosa cell maturity. Immunoreactive inhibin secretion may occur only from healthy mature follicles.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1992.tb01487.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T07:27:33Z","timestamp":1205738853000},"page":"552-557","source":"Crossref","is-referenced-by-count":12,"title":["Immunoreactive inhibin levels during ovarian stimulation may predict granulosa cell maturity"],"prefix":"10.1111","volume":"37","author":[{"given":"H. M.","family":"Buckler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. R.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. D.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-4-798"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1220279"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513599109049942"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03499.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-2-358"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91385-1"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-65-5-954"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000181897"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/clinchem\/28.6.1314","article-title":"Direct 125I\u2010radioligand and assays for serum progesterone compared with assays involving extraction of serum","volume":"28","author":"Ratcliffe W.A.","year":"1982","journal-title":"Clinical Chemistry"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-4-2141"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-3-438"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-4-1208"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)48380-9"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1992.tb01487.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1992.tb01487.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T14:58:12Z","timestamp":1698073092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1992.tb01487.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,12]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1992,12]]}},"alternative-id":["10.1111\/j.1365-2265.1992.tb01487.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb01487.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"type":"print","value":"0300-0664"},{"type":"electronic","value":"1365-2265"}],"subject":[],"published":{"date-parts":[[1992,12]]}}}